Skip to main content

Ibrutinib Given before Surgery in Treating Patients with Prostate Cancer

Trial Status: Active

This phase II trial studies the side effects of ibrutinib and to see how well it works when given before surgery, in treating patients with prostate cancer. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Inclusion Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Histologically documented adenocarcinoma of the prostate
  • Patients must be suitable for and willing to undergo a radical prostatectomy at the completion of study therapy
  • White blood cell (WBC) > 2,500 cells/mm^3
  • Absolute neutrophil count (ANC) > 1,500 cells/mm^3
  • Hemoglobin > 9 mg/dL
  • Platelet count > 100,000 cells/mm^3
  • Serum creatinine < 2 mg/dL or creatinine clearance (CrCl) > 30 mL/min
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x institutional upper limit of normal (ULN)
  • Serum bilirubin < 1.5 x institutional upper limit of normal (ULN)
  • Normal prothrombin time (PT)/international normalized ratio (INR) and partial prothrombin time (PTT)
  • Ability to understand and willingness to sign a written informed consent document
  • Available evaluable archival tumor tissue for correlative studies including assessment of immune infiltration and Btk expression is required; if archival tissue is unavailable, patients must be willing to undergo repeat prostate biopsy; tissue is considered sufficient for correlative endpoint analyses if they are obtained from at least 2 prostate cores and consist of at least 15 unstained slides from the largest tumor volume and/or highest Gleason score; the availability of archival tissue or consent for repeat prostate biopsy is required for study eligibility; determination of tissue sufficiency is not required for study eligibility
  • The effects of ibrutinib on the developing human fetus are unknown; men treated or enrolled on this protocol must agree to use adequate contraception prior to the study, for the duration of the study participation, and for 3 months after completion of treatment

Exclusion Criteria

  • Patients with neuroendocrine or small cell features are not eligible
  • Any evidence of metastatic disease; pre-operative staging will be undertaken per urologic standard of care
  • Any prior use of hormonal therapy, including: * Gonadotrophin releasing hormone (GNRH) agonists or GNRH antagonists (e.g., leuprorelin, degarelix) * Antiandrogens (e.g., bicalutamide, flutamide, nilutamide) * Novel androgen-directed therapies (e.g., abiraterone, enzalutamide) * Any estrogen containing compounds * 5-alpha reductase inhibitors (e.g., finasteride, dutasteride) * PC-SPES or PC-x products; other herbal therapies or supplements will be considered by the principal investigator on a case by case basis based on their potential for hormonal or anti-cancer therapies
  • Chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 6 weeks prior to first administration of study treatment
  • Prior radiation therapy for prostate cancer
  • Prior exposure to BTK inhibitors
  • Prior investigational therapy for prostate cancer
  • Patients may not receive any other concurrent investigational agents while on study
  • Use of systemic steroid therapy within 28 days of study screening; patients on inhaled or topical steroids are eligible
  • Concurrent systemic immunosuppressive therapy within 21 days of the first dose of study drug
  • Major surgery requiring the use of general anesthetic within 4 weeks of study enrollment
  • HIV, active hepatitis B (HBV) or active hepatitis C (HCV) * Patients with past HBV infection or resolved HBV infection, defined as the presence of hepatitis B core antibody (HBc Ab) and absence of hepatitis B surface antigen (HBsAg) are eligible; HBV deoxyribonucleic acid (DNA) must be obtained in these patients prior to day 1 of ibrutinib therapy, but detection of HBV DNA in these patients will not exclude study participation * Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA)
  • Inability to swallow capsules or presence of malabsorption syndromes, disease significantly affecting gastrointestinal function, history of resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete small obstruction
  • Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association Function Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to screening
  • Uncontrolled concurrent illness, or any underlying medical condition, which in the principal investigator’s opinion will make the administration of ibrutinib hazardous or obscure the interpretation of adverse events
  • Recent infection requiring systemic treatment that was completed within 14 days prior to the first dose of study drug
  • Concurrent active malignancy other than non-melanoma skin cancers; patients are considered to be free of active malignancy if they have completed curative therapy and have a < 30% risk of relapse
  • History of congenital bleeding diathesis
  • Known bleeding disorders (e.g. von Willebrand’s disease or hemophilia)
  • Concomitant use of anticoagulants including warfarin, other vitamin K antagonists, and enoxaparin
  • Subjects who received a strong or moderate cytochrome P450 (CYP) 3A4 inhibitor within 7 days prior to the first dose of ibrutinib or patients who require treatment with a strong or moderate cytochrome P450 (CYP) 3A inhibitor
  • Vaccination with live, attenuated vaccines within 4 weeks of first dose of study drug
  • Patients on anti-platelet agents including clopidogrel and glycoprotein IIb/IIIa inhibitors; aspirin is allowed, but should be held before surgery according to standard practices
  • Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child-Pugh classification
  • Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator’s opinion, could compromise the subject’s safety or put the study outcomes at undue risk
  • Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.03 grade 0 or 1 or to the levels dictated in the eligibility criteria with the exception of alopecia


San Francisco
UCSF Medical Center-Mount Zion
Contact: Lawrence Fong
Phone: 415-514-3160


Saint Louis
Siteman Cancer Center at Washington University
Status: ACTIVE
Contact: Russell Kent Pachynski
Phone: 314-286-2341


I. To assess safety in patients with localized prostate cancer.

II. To characterize B and T cell infiltration within prostate tissue of men with localized prostate cancer treated with neoadjuvant ibrutinib, and to compare B and T cell infiltration to a reference population of untreated patients who underwent radical prostatectomy (RP).


I. To characterize changes in the frequency and number of circulating B and T cells induced by neoadjuvant ibrutinib in patients with localized prostate cancer.

II. To determine the cytotoxic effect and clinical benefit of neoadjuvant ibrutinib in men with localized prostate cancer.


I. To examine Btk expression in prostate tumor cells and tumor-infiltrating B cells at baseline before neoadjuvant ibrutinib treatment and at RP after treatment.

II. To determine the impact of neoadjuvant ibrutinib on PD-L1 expression in prostate cancer cells and tumor-infiltrating lymphocytes (TILs).

III. To determine the effects of neoadjuvant ibrutinib on T and B cell repertoire within the tumor and blood.


Patients receive ibrutinib orally (PO) once daily (QD) for 28 days in the absence of disease progression or unaccepted toxicity.

After completion of study treatment, patients are followed up for 4 weeks after RP.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Siteman Cancer Center at Washington University

Principal Investigator
Russell Kent Pachynski

  • Primary ID 201808057
  • Secondary IDs NCI-2017-01748, 15-17517
  • ID NCT02643667